IIIA期皮肤黑色素瘤患者辅助治疗的疗效
这项多中心回顾性研究纳入628例IIIA期皮肤黑色素瘤患者,分别接受辅助抗PD-1治疗、BRAF/MEK靶向治疗(达拉非尼+曲美替尼)或观察。2年无复发生存率抗PD-1组79.3%、靶向治疗组98.6%、观察组84.3%;抗PD-1较观察未显著改善无复发生存或无远处转移生存。靶向治疗优于抗PD-1或观察。
要点
- IIIA期黑色素瘤复发风险中等,辅助抗PD-1较观察未显著改善RFS或DMFS。
- 2年RFS:抗PD-1组79.3%、靶向治疗组98.6%、观察组84.3%。
- ≥3级毒性发生率抗PD-1组10.9%、靶向治疗组17.5%。
核心结论
- IIIA期黑色素瘤复发风险中等,辅助抗PD-1较单纯观察未显著改善RFS或DMFS。
- 辅助靶向治疗(达拉非尼+曲美替尼)相比抗PD-1或观察似乎更有前景。
- 该人群辅助治疗后的结局需在更大数据集、更长随访或前瞻性随机试验中进一步研究。
研究设计与样本
- 多中心回顾性研究,纳入澳大利亚、欧洲和美国34个中心的628例IIIA期皮肤黑色素瘤(AJCC第8版)患者。
- 患者接受辅助帕博利珠单抗或纳武利尤单抗(抗PD-1)256例、BRAF/MEK靶向治疗达拉非尼+曲美替尼80例或无辅助治疗(观察)292例。
- 评估无复发生存(RFS)、无远处转移生存(DMFS)和毒性发生率,中位随访2.6年(四分位距1.6-3.4年)。
主要发现
- 2年RFS:抗PD-1组79.3%(95%CI 74.1%-84.8%),靶向治疗组98.6%(95%CI 96.0%-100%),观察组84.3%(95%CI 79.9%-89.0%)。
- 2年DMFS:抗PD-1组88.4%(95%CI 84.3%-92.8%),靶向治疗组100%,观察组91.1%(95%CI 87.7%-94.7%)。
- 抗PD-1组较观察组存在更多关键不良预后因素。
- 在抗PD-1组和观察组中,较高Breslow厚度和较高核分裂率与更高复发风险相关(P<0.05)。
- ≥3级毒性发生率:抗PD-1组10.9%,靶向治疗组17.5%;因毒性停药率分别为13.3%和21.2%;末次随访时未缓解毒性发生率分别为26.9%和12.5%。
局限性
- 抗PD-1组较观察组存在更多关键不良预后因素。
- 该人群辅助治疗后的结局需在更大数据集、更长随访或前瞻性随机试验中进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with resected American Joint Committee on Cancer eighth edition (AJCC v8) stage IIIA melanoma have been underrepresented in clinical trials of adjuvant drug therapy. The benefit of adjuvant targeted therapy and immunotherapy in this population is unclear. PATIENTS AND METHODS: In this multicentre, retrospective study, patients with stage IIIA melanoma (AJCC v8) who received adjuvant pembrolizumab or nivolumab [anti-programmed cell death protein 1 (PD-1)], BRAF/MEK-targeted therapy dabrafenib + trametinib (TT) or no adjuvant treatment [observation (OBS)] were included. Recurrence-free survival (RFS), distant metastasis-free survival (DMFS) and toxicity rates were examined. RESULTS: A total of 628 patients from 34 centres across Australia, Europe and the United States were identified-256 in anti-PD-1, 80 in TT and 292 in OBS. The median follow-up was 2.6 years (interquartile range 1.6-3.4 years). The presence of some key poor prognostic variables was significantly higher in anti-PD-1 compared with OBS. The 2-year RFS was 79.3% [95% confidence interval (CI) 74.1% to 84.8%] for anti-PD-1, 98.6% (95% CI 96.0% to 100%) for TT and 84.3% (95% CI 79.9% to 89.0%) for OBS. The 2-year DMFS was 88.4% (95% CI 84.3% to 92.8%) in anti-PD-1, 100% in TT and 91.1% (95% CI 87.7% to 94.7%) in OBS. Higher Breslow thickness and higher mitotic rate were associated with higher risk of recurrence in anti-PD-1 and OBS (P < 0.05). Rates of ≥grade 3 toxicities were 10.9% with anti-PD-1 and 17.5% with TT; discontinuation due to toxicity occurred in 13.3% and 21.2%, respectively. Rates of unresolved toxicity at last follow-up were 26.9% in the anti-PD-1 group and 12.5% in the TT group. CONCLUSIONS: Stage IIIA melanoma has a modest risk of recurrence. Adjuvant anti-PD-1 did not significantly improve RFS or DMFS compared with OBS alone. Adjuvant TT appears promising over anti-PD-1 or OBS. Outcomes after adjuvant therapy in this population needs further study in larger datasets with longer follow-up or prospective randomised trials.
引用
- Grover P, Lo SN, Li I, et al. Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma. Ann Oncol. 2025. PMID: 40204154. doi:10.1016/j.annonc.2025.03.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。